FOLD vs. ARWR, BHVN, BHC, PRGO, TPTX, EXAS, RGEN, EXEL, HALO, and IONS
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), Bausch Health Companies (BHC), Perrigo (PRGO), Turning Point Therapeutics (TPTX), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Amicus Therapeutics (NASDAQ:FOLD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Arrowhead Pharmaceuticals had 3 more articles in the media than Amicus Therapeutics. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 5 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.16 beat Arrowhead Pharmaceuticals' score of 0.64 indicating that Amicus Therapeutics is being referred to more favorably in the media.
Amicus Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.
Arrowhead Pharmaceuticals received 7 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.54% of users gave Amicus Therapeutics an outperform vote while only 65.26% of users gave Arrowhead Pharmaceuticals an outperform vote.
Amicus Therapeutics has a net margin of -34.73% compared to Arrowhead Pharmaceuticals' net margin of -163.32%. Amicus Therapeutics' return on equity of -77.08% beat Arrowhead Pharmaceuticals' return on equity.
Amicus Therapeutics has higher revenue and earnings than Arrowhead Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics presently has a consensus target price of $17.57, indicating a potential upside of 79.30%. Arrowhead Pharmaceuticals has a consensus target price of $51.00, indicating a potential upside of 122.22%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Amicus Therapeutics.
Summary
Amicus Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
